Matthias Augustin

A Global Assessment of Patient Experience and Quality of Life in Generalized Pustular Psoriasis: Results from Interviews and Online Surveys

International Consensus Definition and Diagnostic Criteria for Generalized Pustular Psoriasis From the International Psoriasis Council

Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis

S3 Guideline Atopic dermatitis: Part 1 ‐ General aspects, topical and non‐drug therapies, special patient groups

Modelling of patient journey in chronic spontaneous urticaria: Increasing awareness and education by shorten patients' disease journey in Germany

EADV Task Force Pruritus White Paper on chronic pruritus and chronic prurigo: Current challenges and future solutions

Managing dry skin in patients with comorbidities or with advanced age: unmet needs and roles for products containing potential emollient-plus ingredients

Efficacy and safety of guselkumab in European patients with palmoplantar pustulosis: A multi-center, single-arm clinical trial (GAP study)

The socio‐economic burden of H1‐antihistamine‐refractory chronic spontaneous urticaria in Germany

Quality of life measurement in urticaria: Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient‐Oriented Outcomes and Urticaria and Angioedema

Chronic nodular prurigo: Association between comorbidities, itch and quality of life

Quality of life measurement in assessing treatment effectiveness in urticaria: European experts position statement

Basic Susceptibility of Patients with Psoriasis under Systemic Therapy for Respiratory Infections: Data from the German Psoriasis Registry PsoBest

51782 Generalized pustular psoriasis (GPP) continues to adversely impact quality of life between flares, as per Dermatology Life Quality Index scores: Baseline data from the Effisayil 2 trial

Dupilumab but not cyclosporine treatment shifts the microbiome toward a healthy skin flora in patients with moderate‐to‐severe atopic dermatitis

Itching in Atopic Dermatitis: Patient- and Physician-reported Outcomes in the German Atopic Dermatitis Registry TREATgermany

Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis

S3 guideline Atopic dermatitis: Part 2 ‐ Systemic treatment

Quality of life measurement in rosacea. Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa

Implementing well‐being in the management of psoriasis: An expert recommendation

A concept for integrated care pathways for atopic dermatitis—A GA²LEN ADCARE initiative

Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry

Generalized pustular psoriasis: overview of the status quo and results of a panel discussion

Real-World Treatment Patterns and Treatment Benefits among Adult Patients with Atopic Dermatitis: Results from the Atopic Dermatitis Patient Satisfaction and Unmet Need Survey

Registries, multicentre and genome‐wide association studies in hidradenitis suppurativa

Itching and treatments in atopic dermatitis (AD): results from the German AD registry TREATgermany

German S3‐Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – Part 1: Treatment goals and treatment recommendations

German S3‐Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – Part 2: Treatment monitoring and specific clinical or comorbid situations

Association of sex and systemic therapy treatment outcomes in psoriasis: a two‐country, multicentre, prospective, noninterventional registry study*

Update “Systemic treatment of atopic dermatitis” of the S2k‐guideline on atopic dermatitis